Clearside Biomedical Stock News

ALPHARETTA, Ga., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s

ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that multiple oral presentations on Clearside''s SCS injection platform featuring the SCS Microinjector ® were given at the Bascom Palmer Eye Institute''s Angiogenesis, Exudation, and Degeneration 2002 Virtual Event held February 11-12, 2022. Clearside''s presentation, entitled, "The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians" described the preclinical and clinical data demonstrating the methodology and benefits of suprachoroidal delivery. The preclinical data in multiple animal models showed the potential advantages of SCS delivery over intravitreal delivery, the durability potential of small molecule suspensions, and the possible suitability of suprachoroidal delivery for gene therapy. In conjunction with partners, Clearside''s technology is currently being explored in five clinical trials in four indications: neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, uveitic macular edema, and choroidal melanoma. "Suprachoroidal delivery via our SCS Microinjector offers clinicians several potential core benefits for treatment of their patients with back of the eye diseases: targeting of therapy to affected tissues; compartmentalization of therapy to avoid non-diseased tissues; higher bioavailability; and potential longer durability," said Thomas A.

- Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Agents to the Retina and Choroid - - Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Age

Clearside's suprachoroidal space (SCS®) injection platform to be featured at top medical meeting and also at Raymond James Angiogenesis Preview Event Clearside's suprachoroidal space (SCS®) injectio

Clearside Biomedical Inc (CLSD) shares closed today at 0.9% above its 52 week low of $2.21, giving the company a market cap of $139M. The stock is currently down 15.3% year-to-date, down 35.3% over the past 12 months, and down 74.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 38.5% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 2723.8% The company's stock price performance over the past 12 months lags the peer average by 120.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Gainers: Clearside Biomedical (CLSD) +13%, Ebix (EBIX) +7%, Cipher Mining (CIFR) +6%, Array Technologies (ARRY) +5%, Amicus Therapeutics (FOLD) +4%. Losers: Perella Weinberg…

Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.

Clearside Biomedical, Inc. (NASDAQ:CLSD) – Stock analysts at Wedbush reduced their FY2021 EPS estimates for Clearside Biomedical in a research note issued to investors on Tuesday, December 21st. Wedbush analyst A. Argyrides now anticipates that the company will post earnings of ($0.43) per share for the year, down from their prior estimate of ($0.42). Wedbush […]

HC Wainwright reissued their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD) in a research report report published on Wednesday, Price Targets.com reports. The firm currently has a $10.00 price target on the stock. CLSD has been the subject of several other reports. JMP Securities restated a buy rating and set a $11.00 target price []

New Jersey, United States,- Verified Market Research has recently published a research report titled, Diabetic Macular Edema Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Equities analysts forecast that Clearside Biomedical, Inc. (NASDAQ:CLSD) will announce earnings of $0.10 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Clearside Biomedicals earnings, with estimates ranging from ($0.08) to $0.27. Clearside Biomedical reported earnings of ($0.14) per share in the same quarter last year, which []

State Street Corp raised its position in Clearside Biomedical, Inc. (NASDAQ:CLSD) by 316.7% during the second quarter, HoldingsChannel reports. The firm owned 165,588 shares of the companys stock after buying an additional 125,848 shares during the quarter. State Street Corps holdings in Clearside Biomedical were worth $806,000 as of its most recent SEC filing. Several []

Clearside Biomedical, Inc. (NASDAQ:CLSD) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 1,050,000 shares, a drop of 52.3% from the October 31st total of 2,200,000 shares. Based on an average trading volume of 512,500 shares, the short-interest ratio is []